4.3 Review

Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens

期刊

EXPERT REVIEW OF RESPIRATORY MEDICINE
卷 6, 期 5, 页码 533-555

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERS.12.45

关键词

Acinetobacter baumannii; antibacterial agents; artificial respiration; beta-lactamase; carbapenemase; critical illness; drug resistance; intensive care; intratracheal intubation; methicillin-resistant Staphylococcus aureus; Pseudomonas aeruginosa; ventilator-associated pneumonia

资金

  1. Pfizer

向作者/读者索取更多资源

Ventilator-associated pneumonia (VAP) due to multidrug-resistant (MDR) pathogens is a leading healthcare-associated infection in mechanically ventilated patients. The incidence of VAP due to MDR pathogens has increased significantly in the last decade. Risk factors for VAP due to MDR organisms include advanced age, immunosuppression, broad-spectrum antibiotic exposure, increased severity of illness, previous hospitalization or residence in a chronic care facility and prolonged duration of invasive mechanical ventilation. Methicillin-resistant Staphlococcus aureus and several different species of Gram-negative bacteria can cause MDR VAP. Especially difficult Gram-negative bacteria include Pseudomonas aeruginosa, Acinetobacter baumannii, carbapenemase-producing Enterobacteraciae and extended-spectrum beta-lactamase producing bacteria. Proper management includes selecting appropriate antibiotics, optimizing dosing and using timely de-escalation based on antibimicrobial sensitivity data. Evidence-based strategies to prevent VAP that incorporate multidisciplinary staff education and collaboration are essential to reduce the burden of this disease and associated healthcare costs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据